Profile data is unavailable for this security.
About the company
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
- Revenue in USD (TTM)0.00
- Net income in USD-30.74m
- Incorporated2005
- Employees92.00
- LocationXBiotech Inc5217 WINNEBAGO LANEAUSTIN 78744United StatesUSA
- Phone+1 (512) 386-2900
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc | 301.87m | -59.29m | 208.80m | 249.00 | -- | -- | -- | 0.6917 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 211.48m | 128.00 | -- | 1.00 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Generation Bio Co | 9.96m | -169.06m | 211.56m | 174.00 | -- | 1.60 | -- | 21.23 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 217.09m | 40.00 | -- | 2.77 | -- | 458.45 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 217.44m | 274.00 | -- | 1.05 | -- | 3.05 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Invivyd Inc | 0.00 | -206.82m | 219.54m | 94.00 | -- | 1.23 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 219.65m | 29.00 | -- | 2.74 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 219.78m | 11.00 | -- | 1.30 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 220.24m | 51.00 | -- | 1.19 | -- | 13.64 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| XBiotech Inc | 0.00 | -30.74m | 220.82m | 92.00 | -- | 1.05 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 224.29m | 9.00 | -- | 2.01 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 224.44m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 224.66m | 46.00 | -- | 1.90 | -- | 13.85 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 228.80m | 57.00 | -- | 0.8488 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 229.34m | 10.00 | -- | 2.02 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to XBiotech Inc's reporting currency: US Dollar USD
10.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Mar 2024 | 927.37k | 3.05% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 891.02k | 2.93% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 265.32k | 0.87% |
| Credit Suisse AGas of 31 Mar 2024 | 248.27k | 0.82% |
| Geode Capital Management LLCas of 31 Mar 2024 | 195.20k | 0.64% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 169.81k | 0.56% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 149.32k | 0.49% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 112.99k | 0.37% |
| Connor, Clark & Lunn Investment Management Ltd.as of 31 Mar 2024 | 77.41k | 0.25% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 72.48k | 0.24% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
